and mortality. Similar HbA1c reductions were observed in
both groups from baseline to week 52; however, during the
extension periods, the attenuation of HbA1c reduction was
less pronounced in the dapagliflozin group than in the glipizide
group. The 208-week coefficient of failure was lower
with dapagliflozin than with glipizide, with a significant difference
of −0.42 (0.0001; full analysis set), thus pointing to
more sustained glycaemic efficacy with dapagliflozin therapy.
Results for FPG were consistent with those for HbA1c.While
it should be noted that these results are based on a diminishing
number of patients during the extension periods, the durability
of glycaemic response was observed irrespective of the
inclusion or exclusion of data after rescue (intent-to treat vs
completers).